Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T32335 Target Info
Target Name Inhibitor of nuclear factor kappa-B kinase (IKK)
Synonyms IB kinase; IkappaB kinase; IKK
Target Type Patented-recorded Target
Gene Name NO-GeName
UniProt ID
NOUNIPROTAC
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2011077502
Title Dihydrothieno[2,3-E]Indazole Compound.
Abstract Disclosed is a novel compound which has excellent IkappaB kinase inhibitory activity and TNFalpha production inhibitory activity, and is used as an active ingredient for an agent for prevention or treatment of diseases associated with NF-kappaB and TNFalpha. Specifically disclosed is a novel dihydrothieno[2,3-e]indazole compound represented by formula (1). Also specifically disclosed are a pharmaceutical composition containing the dihydrothieno[2,3-e]indazole compound, and use of the dihydrothieno[2,3-e]indazole compound for prevention or treatment of diseases.
Applicant(s) Kyorin Seiyaku Kk
Representative Drug(s) D04HQH Drug Info N.A. Click to Show More [1]
2 D07DBU Drug Info N.A. [1]
3 D0EX5A Drug Info N.A. [1]
4 D0T1MA Drug Info N.A. [1]
Patent ID WO2009074809
Title Sigma Ligands and Ikk / Nf - Kb Inhibitors for Medical Treatment.
Abstract The present invention relates to agents that act in concert with sigma receptor ligands to enhance their effectiveness in the treatment of cancer and inflammatory disease. It also relates to methods whereby agents can be identified that will be of use in combination with sigma ligands in the treatment of the aforesaid diseases.
Applicant(s) University of Dundee
Patent ID WO2009030890
Title Pyrimidine Compounds for The Treatment of Cancer, Septic Shock and/or Primary Open Angle Glaucoma.
Abstract The present invention relates to the use of certain pyrimidine compounds to inhibit, for example, TBKl and/or IKK epsilon and which may therefore find application in treating cancer septic shock and/or Primary open Angle Glaucoma (POAG).
Applicant(s) University Court of the University of Dundee
References  Top
REF 1 Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
REF 2 Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
REF 3 TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.